Several drugs targeting HER2 have been approved for the treatment of HER2-positive breast cancer including monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs) [3]. The gene discussed is ERBB2; the disease is breast cancer.